Scryb -- ehemals Vervielfachungschance_ChroMedX (Seite 985)
eröffnet am 23.10.14 08:22:42 von
neuester Beitrag 23.04.24 11:29:22 von
neuester Beitrag 23.04.24 11:29:22 von
Beiträge: 12.079
ID: 1.201.093
ID: 1.201.093
Aufrufe heute: 7
Gesamt: 1.267.545
Gesamt: 1.267.545
Aktive User: 0
ISIN: CA81111V1076 · WKN: A3C86A · Symbol: EIY
0,0190
EUR
+18,75 %
+0,0030 EUR
Letzter Kurs 26.04.24 Tradegate
Werte aus der Branche Informationstechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5400 | +176,92 | |
| 1,5000 | +20,00 | |
| 174,60 | +20,00 | |
| 122,64 | +20,00 | |
| 220,00 | +18,60 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,5500 | -18,17 | |
| 20,06 | -19,76 | |
| 18,96 | -22,61 | |
| 1,1200 | -31,71 | |
| 5,0500 | -43,73 |
Beitrag zu dieser Diskussion schreiben
Feedback
Ich kenne dieses Schreiben und es ist mir klar, dass das Produkt noch weiter verbessert werden muss. Apple hat den Markt auch nicht mit dem iPhone X erobert sondern jedes Jahr an der Verbesserung gearbeitet.
Auszug aus
https://webfiles.thecse.com/Relay_MDA_2018-06-30_Final.pdf?d…
aus gegebenen Anlass.
Results of operations
HemoPalm
HemoPalm, the Company’s lead product is a handheld whole blood analyzer and single-use cartridge, with full hospital IT integration, which bring lab-quality blood analysis to the bedside in critical care.
The technical development and design planning of Relay’s HemoPalm has been focused on an “enterprise solution” approach, integration with existing hospital infrastructure, and design flexibility, a
iming to reduce barriers to adoption at every layer of the enterprise.
The Company’s view of the market for the Hemo Palm product is that the market expects a “total
solution” approach and design excellence in every aspect of the product, touching upon the value
drivers for all of the key stakeholders who rely on the product.
Thorough analysis is being conducted on areas including distributed QA and training, the accountability of the lab and the Clinical Biochemist, cost structures and reimbursements, logistics and consumables management, workflow and reduction of pre-analytical errors, future test panel introductions, integration with hospital IT, security and fleet management to be incorporated into the product design specifications - compiling the information into the User Experience (UX) and the Total Ownership Experience (TOX), which all of the stakeholders in the hospital, experience.
Relay currently has a techno-commercial team of 8 people actively focused on the HemoPalm
project, including the recently retained senior consultant and blood gas industry veteran Andy
Mac. In previous roles, Mr. Mac contributed to the development of the iStat cartridge technology
and was instrumental to the Epocal product development and cartridge manufacturing line design.
Relay has also assembled a senior strategic team spearheaded by Medtech Executive and strategist
John Soloninka to lead “voice of customer” analysis and to investigate the value maximization of
the HemoPalm asset. The Company continues to consult with counsel and advisors to further
optimize intellectual property protection both as a core asset and as blocking IP for larger
competitors who, the Company believes need to incorporate the HemoPalm technology into their
products.
The Company has received considerable feedback from the voice of customer research initiative
including detailed correspondence with key-opinion leaders (KOLs) in the ICU and NICU.
Preliminary feedback indicates a clear clinical need for the HemoPalm IP and for the integration
of decentralized POCT testing devices for rapid clinical decision making as part of an enterprise
solution in hospitals, for process improvement, QA and training.
Chief Science Officer Dr. Tom Glawdel continues to lead technical advancement as Relay works
towards the development and productization of world class CO-Oximeter technology in a
handheld form factor. Testing is being conducted on three bench-top spectrometer setups.
Historical data from experiments have been run through the technology’s new software setup and
are generating some promising results. A cloud data collection system has been built and testing
on synthetic blood will commence within the next few weeks.
In 2017 the Relay development team focused on the research, development, benchmarking,
modeling and validating of the core components of the HemoPalm technology. During the first half of 2018, the Company’s techno-commercial team has conducted in-depth market research and analysis to outline product strategy and exit requirements to define the HemoPalm feature set,
path to the market, technical implementation roadmap and productization plan.
https://webfiles.thecse.com/Relay_MDA_2018-06-30_Final.pdf?d…
aus gegebenen Anlass.
Results of operations
HemoPalm
HemoPalm, the Company’s lead product is a handheld whole blood analyzer and single-use cartridge, with full hospital IT integration, which bring lab-quality blood analysis to the bedside in critical care.
The technical development and design planning of Relay’s HemoPalm has been focused on an “enterprise solution” approach, integration with existing hospital infrastructure, and design flexibility, a
iming to reduce barriers to adoption at every layer of the enterprise.
The Company’s view of the market for the Hemo Palm product is that the market expects a “total
solution” approach and design excellence in every aspect of the product, touching upon the value
drivers for all of the key stakeholders who rely on the product.
Thorough analysis is being conducted on areas including distributed QA and training, the accountability of the lab and the Clinical Biochemist, cost structures and reimbursements, logistics and consumables management, workflow and reduction of pre-analytical errors, future test panel introductions, integration with hospital IT, security and fleet management to be incorporated into the product design specifications - compiling the information into the User Experience (UX) and the Total Ownership Experience (TOX), which all of the stakeholders in the hospital, experience.
Relay currently has a techno-commercial team of 8 people actively focused on the HemoPalm
project, including the recently retained senior consultant and blood gas industry veteran Andy
Mac. In previous roles, Mr. Mac contributed to the development of the iStat cartridge technology
and was instrumental to the Epocal product development and cartridge manufacturing line design.
Relay has also assembled a senior strategic team spearheaded by Medtech Executive and strategist
John Soloninka to lead “voice of customer” analysis and to investigate the value maximization of
the HemoPalm asset. The Company continues to consult with counsel and advisors to further
optimize intellectual property protection both as a core asset and as blocking IP for larger
competitors who, the Company believes need to incorporate the HemoPalm technology into their
products.
The Company has received considerable feedback from the voice of customer research initiative
including detailed correspondence with key-opinion leaders (KOLs) in the ICU and NICU.
Preliminary feedback indicates a clear clinical need for the HemoPalm IP and for the integration
of decentralized POCT testing devices for rapid clinical decision making as part of an enterprise
solution in hospitals, for process improvement, QA and training.
Chief Science Officer Dr. Tom Glawdel continues to lead technical advancement as Relay works
towards the development and productization of world class CO-Oximeter technology in a
handheld form factor. Testing is being conducted on three bench-top spectrometer setups.
Historical data from experiments have been run through the technology’s new software setup and
are generating some promising results. A cloud data collection system has been built and testing
on synthetic blood will commence within the next few weeks.
In 2017 the Relay development team focused on the research, development, benchmarking,
modeling and validating of the core components of the HemoPalm technology. During the first half of 2018, the Company’s techno-commercial team has conducted in-depth market research and analysis to outline product strategy and exit requirements to define the HemoPalm feature set,
path to the market, technical implementation roadmap and productization plan.
Antwort auf Beitrag Nr.: 58.578.779 von greatbull am 31.08.18 08:32:13Das Ganze läuft seit 2014. Bis jetzt keine Revenues, Warants, Firmenkäufe, Steigende Aktienzahlen usw. Ein Spassvogel hat sogar behauptet, dass er den Hemopalm in einem Ambulanzwagen im Einsatz gesehen hat. Die Story der Studentin, die ein Riesenvermögen ohne Produkt aufgebaut hat ist ja auch bekannt bis die bittere Wahrheit ans Licht kam. Der Sturz war tief. Dass da manchmal Zweifel aufkommen ist doch klar. Wenn es dann um die FDA-Zulassung geht, heisst es, das hätte die Firma nie gesagt und kam nur aus der Feder eines Börsenbriefschreibers. Darum wäre ich gerne zur GV gefahren, um mir persönlich ein Bild zu machen. Musste den Plan allerdings verwerfen. Du fragst mich nach Beweisen, Hast denn Du welche?
Antwort auf Beitrag Nr.: 58.569.305 von LittleElephant am 30.08.18 10:44:38
LittleElephant bitte!!!
Fakten zur Sache, keine sich wiederholende Mutmaßungen.
gb 3:-)
LittleElephant bitte!!!
Fakten zur Sache, keine sich wiederholende Mutmaßungen.
gb 3:-)
Antwort auf Beitrag Nr.: 58.568.426 von LittleElephant am 30.08.18 09:44:28
LittleElephant,
Die Frankfurter Börse, unterschreitet 10.000 er Stückzahlen, daß Relay Medicals Wertpapier verliert an Wertugen.
Kann das Zufall sein, oder steckt da ein großes Interesse dahinter,vielleicht wissen da einige mehr über FDA-Zulassung bescheid, und schweigen bis mehr im Briefkurs an verkauften Stücken ansammelt.
Zitat von LittleElephant: Nicht Nut mit der Bafin. Darum wäre es mehr als wichtig, dass er Hemopalm die FDA-Zulassung bekommt. Da das Produkt durch Patente geschützt ist, verstehe ich nicht, warum diese Zulassung nicht endlich in Angriff genommen wird. Einer Verbesserung des Produktes steht da nichts entgegen. Ohne diese Zulassung ist es eine hohle Nuss.
LittleElephant,
Die Frankfurter Börse, unterschreitet 10.000 er Stückzahlen, daß Relay Medicals Wertpapier verliert an Wertugen.
Kann das Zufall sein, oder steckt da ein großes Interesse dahinter,vielleicht wissen da einige mehr über FDA-Zulassung bescheid, und schweigen bis mehr im Briefkurs an verkauften Stücken ansammelt.
Trading Spotlight
Sehr lesenswert:
https://webfiles.thecse.com/Relay_MDA_2018-06-30_Final.pdf?d…
Relay Medical Corp.
(formerly ChroMedX Corp.)
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
FOR THE
NINE
MONTHS ENDED
JUNE
30, 2018
https://webfiles.thecse.com/Relay_MDA_2018-06-30_Final.pdf?d…
Relay Medical Corp.
(formerly ChroMedX Corp.)
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
FOR THE
NINE
MONTHS ENDED
JUNE
30, 2018
Antwort auf Beitrag Nr.: 58.568.852 von Jet-Stream am 30.08.18 10:13:23Das ist die Frage. Existiert das Produkt und wenn ja, warum kümmert man sich nicht um die Zulassung? Eine möglichen Verbesserung würde danach nichts entgegenstehen, da das Geistige Eigentum ja geschützt ist. Das Vertrauen der Aktionäre wäre wieder hergestellt. Diese Strategie verstehe ich wirklich nicht.
Antwort auf Beitrag Nr.: 58.568.426 von LittleElephant am 30.08.18 09:44:28Wie kann etwas zugekassen werden dass garnicht existiert.
Antwort auf Beitrag Nr.: 58.566.896 von Takado am 30.08.18 07:34:56Nicht Nut mit der Bafin. Darum wäre es mehr als wichtig, dass er Hemopalm die FDA-Zulassung bekommt. Da das Produkt durch Patente geschützt ist, verstehe ich nicht, warum diese Zulassung nicht endlich in Angriff genommen wird. Einer Verbesserung des Produktes steht da nichts entgegen. Ohne diese Zulassung ist es eine hohle Nuss.
Antwort auf Beitrag Nr.: 58.555.847 von geldmanager am 28.08.18 22:54:27Du weisst schon, dass die ärger mit der bafin hatten?
Durchsuchen
Scryb -- ehemals Vervielfachungschance_ChroMedX
